Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$0.69 USD
+0.02 (2.65%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $0.70 +0.01 (0.84%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Verrica Pharmaceuticals Inc. (VRCA) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $7.75 | $12.00 | $2.00 | 1,039.71% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Verrica Pharmaceuticals Inc. comes to $7.75. The forecasts range from a low of $2.00 to a high of $12.00. The average price target represents an increase of 1% from the last closing price of $0.68.
Analyst Price Targets (4 )
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
Verrica Pharmaceuticals Inc. currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, two are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 4 |
| Buy | 0 | 0 | 0 | 1 | 2 |
| Hold | 4 | 4 | 4 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 2.33 | 2.33 | 2.33 | 1.83 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 11/6/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Hold |
| 11/5/2024 | Not Identified | Not Identified | Moderate Buy | Hold |
| 10/3/2024 | Needham & Company | Serge Belanger | Moderate Buy | Hold |
| 10/2/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Hold |
| 8/15/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
| 5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 2.33 |
| ABR (Last week) | 2.33 |
| # of Recs in ABR | 6 |
| Average Target Price | $7.75 |
| LT Growth Rate | NA |
| Industry | Medical - Drugs |
| Industry Rank by ABR | 73 of 251 |
| Current Quarter EPS Est: | -0.23 |
VRCA FAQs
Verrica Pharmaceuticals Inc. (VRCA) currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Verrica Pharmaceuticals Inc. (VRCA) is $7.75. The current on short-term price targets is based on 2 reports.
The forecasts for Verrica Pharmaceuticals Inc. (VRCA) range from a low of $2 to a high of $12. The average price target represents a increase of $1023.19 from the last closing price of $0.69.
The current UPSIDE for Verrica Pharmaceuticals Inc. (VRCA) is 1023.19%
Based on short-term price targets offered by four analysts, the average price target for Verrica Pharmaceuticals Inc. comes to $7.75. The forecasts range from a low of $2.00 to a high of $12.00. The average price target represents an increase of 1% from the last closing price of $0.68.